Conditional survival of stage III non-seminoma testis cancer patients

Reha-Baris Incesu; Francesco Barletta; Stefano Tappero; Simone Morra; Cristina Cano Garcia; Lukas Scheipner; Mattia Luca Piccinelli; Zhe Tian; Fred Saad; Shahrokh F Shariat; Ottavio de Cobelli; Sascha Ahyai; Felix K H Chun; Nicola Longo; Carlo Terrone; Alberto Briganti; Derya Tilki; Markus Graefen; Pierre I Karakiewicz

doi:10.1016/j.urolonc.2023.06.005

Conditional survival of stage III non-seminoma testis cancer patients

Standard

Conditional survival of stage III non-seminoma testis cancer patients. / Incesu, Reha-Baris; Barletta, Francesco; Tappero, Stefano; Morra, Simone; Garcia, Cristina Cano; Scheipner, Lukas; Piccinelli, Mattia Luca; Tian, Zhe; Saad, Fred; Shariat, Shahrokh F; de Cobelli, Ottavio; Ahyai, Sascha; Chun, Felix K H; Longo, Nicola; Terrone, Carlo; Briganti, Alberto; Tilki, Derya; Graefen, Markus; Karakiewicz, Pierre I.

in: UROL ONCOL-SEMIN ORI, Jahrgang 41, Nr. 10, 10.2023, S. 435.e11-435.e18.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Incesu, R-B, Barletta, F, Tappero, S, Morra, S, Garcia, CC, Scheipner, L, Piccinelli, ML, Tian, Z, Saad, F, Shariat, SF, de Cobelli, O, Ahyai, S, Chun, FKH, Longo, N, Terrone, C, Briganti, A, Tilki, D, Graefen, M & Karakiewicz, PI 2023, 'Conditional survival of stage III non-seminoma testis cancer patients', UROL ONCOL-SEMIN ORI, Jg. 41, Nr. 10, S. 435.e11-435.e18. https://doi.org/10.1016/j.urolonc.2023.06.005

APA

Incesu, R-B., Barletta, F., Tappero, S., Morra, S., Garcia, C. C., Scheipner, L., Piccinelli, M. L., Tian, Z., Saad, F., Shariat, S. F., de Cobelli, O., Ahyai, S., Chun, F. K. H., Longo, N., Terrone, C., Briganti, A., Tilki, D., Graefen, M., & Karakiewicz, P. I. (2023). Conditional survival of stage III non-seminoma testis cancer patients. UROL ONCOL-SEMIN ORI, 41(10), 435.e11-435.e18. https://doi.org/10.1016/j.urolonc.2023.06.005

Vancouver

Incesu R-B, Barletta F, Tappero S, Morra S, Garcia CC, Scheipner L et al. Conditional survival of stage III non-seminoma testis cancer patients. UROL ONCOL-SEMIN ORI. 2023 Okt;41(10):435.e11-435.e18. https://doi.org/10.1016/j.urolonc.2023.06.005

Bibtex

@article{9ba56502fb49493c8b0707c438ace395,

title = "Conditional survival of stage III non-seminoma testis cancer patients",

abstract = "PURPOSE: In many primaries other than non-seminoma testis cancer, the risk of death due to cancer decreases with increasing disease-free interval duration after initial diagnosis and treatment. This effect is known as conditional survival and is relatively unexplored in stage III non-seminoma patients, where it may matter most in clinical decision-making. We examined the effect of disease-free interval duration on overall survival in stage III non-seminoma patients.MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results Database (2004-2018), stage III non-seminoma patients were identified. Multivariable Cox regression analyses and conditional survival models were applied.RESULTS: Of 2,092 surgically treated stage III non-seminoma patients, 385 (18%) exhibited good vs. 558 (27%) intermediate vs. 1,149 (55%) poor prognosis. In multivariable Cox regression models, poor prognosis group independently predicted overall mortality (HR 3.3, P < 0.001). In conditional survival analyses based on 36 months' disease-free interval duration, 5-year overall survival estimates were as follows: good prognosis patients 96 vs. 89% at initial diagnosis without accounting for disease-free interval duration (Δ=+7); intermediate prognosis patients 94 vs. 85% at initial diagnosis without accounting for disease-free interval duration (Δ=+9); poor prognosis patients 94 vs. 65% at initial diagnosis without accounting for disease-free interval duration (Δ=+29).CONCLUSIONS: Conditional survival estimates based on 36 months' disease-free interval duration provide a more accurate and more optimistic outlook for stage III non-seminoma patients than predictions defined at initial diagnosis, without accounting for disease-free interval duration.",

keywords = "Male, Humans, Neoplasm Staging, Testicular Neoplasms/pathology, Prognosis, Survival Analysis, Seminoma/pathology",

author = "Reha-Baris Incesu and Francesco Barletta and Stefano Tappero and Simone Morra and Garcia, {Cristina Cano} and Lukas Scheipner and Piccinelli, {Mattia Luca} and Zhe Tian and Fred Saad and Shariat, {Shahrokh F} and {de Cobelli}, Ottavio and Sascha Ahyai and Chun, {Felix K H} and Nicola Longo and Carlo Terrone and Alberto Briganti and Derya Tilki and Markus Graefen and Karakiewicz, {Pierre I}",

year = "2023",

month = oct,

doi = "10.1016/j.urolonc.2023.06.005",

language = "English",

volume = "41",

pages = "435.e11--435.e18",

journal = "UROL ONCOL-SEMIN ORI",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "10",

}

RIS

TY - JOUR

T1 - Conditional survival of stage III non-seminoma testis cancer patients

AU - Incesu, Reha-Baris

AU - Barletta, Francesco

AU - Tappero, Stefano

AU - Morra, Simone

AU - Garcia, Cristina Cano

AU - Scheipner, Lukas

AU - Piccinelli, Mattia Luca

AU - Tian, Zhe

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - de Cobelli, Ottavio

AU - Ahyai, Sascha

AU - Chun, Felix K H

AU - Longo, Nicola

AU - Terrone, Carlo

AU - Briganti, Alberto

AU - Tilki, Derya

AU - Graefen, Markus

AU - Karakiewicz, Pierre I

PY - 2023/10

Y1 - 2023/10

N2 - PURPOSE: In many primaries other than non-seminoma testis cancer, the risk of death due to cancer decreases with increasing disease-free interval duration after initial diagnosis and treatment. This effect is known as conditional survival and is relatively unexplored in stage III non-seminoma patients, where it may matter most in clinical decision-making. We examined the effect of disease-free interval duration on overall survival in stage III non-seminoma patients.MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results Database (2004-2018), stage III non-seminoma patients were identified. Multivariable Cox regression analyses and conditional survival models were applied.RESULTS: Of 2,092 surgically treated stage III non-seminoma patients, 385 (18%) exhibited good vs. 558 (27%) intermediate vs. 1,149 (55%) poor prognosis. In multivariable Cox regression models, poor prognosis group independently predicted overall mortality (HR 3.3, P < 0.001). In conditional survival analyses based on 36 months' disease-free interval duration, 5-year overall survival estimates were as follows: good prognosis patients 96 vs. 89% at initial diagnosis without accounting for disease-free interval duration (Δ=+7); intermediate prognosis patients 94 vs. 85% at initial diagnosis without accounting for disease-free interval duration (Δ=+9); poor prognosis patients 94 vs. 65% at initial diagnosis without accounting for disease-free interval duration (Δ=+29).CONCLUSIONS: Conditional survival estimates based on 36 months' disease-free interval duration provide a more accurate and more optimistic outlook for stage III non-seminoma patients than predictions defined at initial diagnosis, without accounting for disease-free interval duration.

AB - PURPOSE: In many primaries other than non-seminoma testis cancer, the risk of death due to cancer decreases with increasing disease-free interval duration after initial diagnosis and treatment. This effect is known as conditional survival and is relatively unexplored in stage III non-seminoma patients, where it may matter most in clinical decision-making. We examined the effect of disease-free interval duration on overall survival in stage III non-seminoma patients.MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results Database (2004-2018), stage III non-seminoma patients were identified. Multivariable Cox regression analyses and conditional survival models were applied.RESULTS: Of 2,092 surgically treated stage III non-seminoma patients, 385 (18%) exhibited good vs. 558 (27%) intermediate vs. 1,149 (55%) poor prognosis. In multivariable Cox regression models, poor prognosis group independently predicted overall mortality (HR 3.3, P < 0.001). In conditional survival analyses based on 36 months' disease-free interval duration, 5-year overall survival estimates were as follows: good prognosis patients 96 vs. 89% at initial diagnosis without accounting for disease-free interval duration (Δ=+7); intermediate prognosis patients 94 vs. 85% at initial diagnosis without accounting for disease-free interval duration (Δ=+9); poor prognosis patients 94 vs. 65% at initial diagnosis without accounting for disease-free interval duration (Δ=+29).CONCLUSIONS: Conditional survival estimates based on 36 months' disease-free interval duration provide a more accurate and more optimistic outlook for stage III non-seminoma patients than predictions defined at initial diagnosis, without accounting for disease-free interval duration.

KW - Male

KW - Humans

KW - Neoplasm Staging

KW - Testicular Neoplasms/pathology

KW - Prognosis

KW - Survival Analysis

KW - Seminoma/pathology

U2 - 10.1016/j.urolonc.2023.06.005

DO - 10.1016/j.urolonc.2023.06.005

M3 - SCORING: Journal article

C2 - 37558516

VL - 41

SP - 435.e11-435.e18

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 10

ER -